Table 1. Patient characteristics at baseline stratified by the concomitant diabetes medications.
| Characteristic | Total (n=8,636) |
Group A (n=1,437) |
Group B (n=4,402) |
Group C (n=2,658) |
Group D (n=139) |
P value |
|---|---|---|---|---|---|---|
| Male sex | 4,698 (54.4) | 805 (56.0) | 2,352 (53.4) | 1,466 (55.2) | 75 (54.0) | 0.0237 |
| Age, yr | 58.1±11.4 | 57.7±11.6 | 58.2±11.4 | 58.5±11.0 | 54.2±14.0 | <0.0001 |
| Body weight, kg | 65.2±10.3 | 64.5±9.6 | 65.2±10.2 | 65.8±10.6 | 62.4±12.7 | <0.0001 |
| Waist circumference, cm | 84.5±10.6 | 83.0±10.3 | 84.7±10.3 | 85.0±11.1 | 81.0±9.1 | <0.0001 |
| BMI, kg/m2 | 24.3±2.8 | 23.9±2.7 | 24.2±2.7 | 24.6±2.9 | 23.1±4.1 | <0.0001 |
| Duration of diabetes, yr | 8.9±5.9 | 7.4±5.3 | 8.8±5.8 | 9.9±6.2 | 9.0±6.6 | <0.0001 |
| HbA1c, % | 9.2±1.4 | 8.9±1.4 | 9.1±1.4 | 9.4±1.5 | 10.4±2.0 | <0.0001 |
| HbA1c, mmol/mol | ||||||
| FBG, mg/dL | 200.8±61.9 | 189.0±63.1 | 197.3±54.9 | 210.9±67.0 | 237.6±107.1 | <0.0001 |
| PP2BG, mg/dL | 279.3±79.2 | 257.2±77.4 | 280.9±78.0 | 286.7±78.8 | 327.1±105.7 | <0.0001 |
| Prior therapy | ||||||
| Sulphonylurea | 7,217 (83.6) | 1,191 (82.9) | 3,612 (82.1) | 2,332 (87.7) | 82 (59.0) | <0.0001 |
| Metformin | 5,654 (65.5) | 770 (53.6) | 2,625 (59.6) | 2,176 (81.9) | 83 (59.7) | <0.0001 |
| α-Glucosidase inhibitor | 1,795 (20.8) | 197 (13.7) | 821 (18.7) | 748 (28.1) | 29 (20.9) | <0.0001 |
| Thiazolidinedione | 900 (10.4) | 101 (7.0) | 534 (12.1) | 251 (9.4) | 14 (10.1) | <0.0001 |
| Meglitinide | 600 (7.0) | 70 (4.9) | 372 (8.5) | 154 (5.8) | 4 (2.9) | <0.0001 |
Values are presented as number (%) or mean±standard deviation. Group A: basal insulin only, group B: basal insulin+1 OHA, group C: basal insulin+≥2 OHAs, and group D: basal insulin+short acting insulin.
BMI, body mass index; HbA1c, glycosylated hemoglobin; FBG, fasting blood glucose; PP2BG, postprandial 2-hour blood glucose.